Shree Ganesh Remedies Limited

BSE:540737 Stock Report

Market Cap: ₹8.9b

Shree Ganesh Remedies Past Earnings Performance

Past criteria checks 6/6

Shree Ganesh Remedies has been growing earnings at an average annual rate of 25.8%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 20.6% per year. Shree Ganesh Remedies's return on equity is 20.9%, and it has net margins of 22.7%.

Key information

25.8%

Earnings growth rate

24.6%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate20.6%
Return on equity20.9%
Net Margin22.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shree Ganesh Remedies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:540737 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,2292791100
30 Jun 241,240280920
31 Mar 241,259281980
31 Dec 231,174220820
30 Sep 231,115215780
30 Jun 23993189610
31 Mar 23902170700
31 Dec 22815150740
30 Sep 22806148710
30 Jun 22763139510
31 Mar 22713134480
31 Dec 21661126780
30 Sep 21582112760
30 Jun 21515101740
31 Mar 2149198730
31 Dec 2049994560
30 Sep 2052992740
30 Jun 2058899710
31 Mar 20648105690
31 Dec 1957295550
30 Sep 1949786400
30 Jun 1942574380
31 Mar 1935362370
31 Dec 1835256350
30 Sep 1835049330
30 Jun 1831248350
31 Mar 1827347360
31 Mar 1719926260
31 Mar 1615511240
31 Mar 1516513240
31 Mar 1418332230

Quality Earnings: 540737 has high quality earnings.

Growing Profit Margin: 540737's current net profit margins (22.7%) are higher than last year (19.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 540737's earnings have grown significantly by 25.8% per year over the past 5 years.

Accelerating Growth: 540737's earnings growth over the past year (29.4%) exceeds its 5-year average (25.8% per year).

Earnings vs Industry: 540737 earnings growth over the past year (29.4%) exceeded the Pharmaceuticals industry 20.5%.


Return on Equity

High ROE: 540737's Return on Equity (20.9%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies